City Therapeutics(NASDAQ) CTY

Market Cap$1.13B

Since IPO (2026)+24%

5 YearN/A

1 YearN/A

1 MonthN/A

$22.25

+23.58%

+4.24Today

After hours$21.70-$0.55 (-2.45%)

City Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 22.40	2026-10-16

City Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
Since inception	+24.44%	USD 18.00	2026-10-14

City Therapeutics Financials at a Glance

Market Cap

$1.13B

Revenue (TTM)

$6.49B

Net Income (TTM)

$1.80B

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$22.25

Volume

1,406,423.007

Open

$23.00

Price

$22.25

Volume

1,406,423.007

Open

$23.00

Previous Close

$22.40

Daily Range

$20.50 - $23.88

52-Week Range

$18.00 - $23.88

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$22.25

Volume

1,406,423.007

Open

$23.00

Previous Close

$22.40

Daily Range

$20.50 - $23.88

52-Week Range

$18.00 - $23.88

Estimated Earnings Date

N/A

CTY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About City Therapeutics

City Therapeutics Inc. is a biotechnology company focused on developing next-generation RNA interference (RNAi) therapeutics. Based in Cambridge, MA, the company aims to deliver potent and specific RNAi trigger molecules to treat various conditions, including ocular and central nervous system diseases.

Products and Services

Development of RNAi therapeutics targeting thromboembolic diseases
Innovative treatments for Stargardt disease and other ocular conditions
Research programs addressing hepatic and CNS disorders

Growth Outlook

Strong pipeline with lead candidates CITY-FXI and CITY-RBP4
Potential to address significant unmet medical needs in multiple therapeutic areas
Strategic partnerships may enhance research and development capabilities

Financial Highlights

Recent quarterly revenue of $524 million, showcasing robust market demand
Trailing twelve months (TTM) net income margin of 22.4%, indicating profitability
Operating cash flow of $699 million in the latest quarter, reflecting strong operational efficiency

City Therapeutics Inc. is positioned to capitalize on the growing demand for innovative therapies in the biotechnology sector. The company's focus on RNAi technology offers a unique approach to treating complex diseases, potentially leading to significant advancements in patient care. With a solid financial foundation and a promising pipeline, City Therapeutics Inc. presents an intriguing opportunity for investors interested in the biotechnology landscape.

AI Generated • Oct 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Andrew C. Orth, MBA

Website

www.citytx.com

Headquarters

Cambridge, MA, US

CTY Financials

Key Financial Metrics (TTM)

Gross Margin

70.11%

Operating Margin

35.36%

Net Income Margin

22.40%

Return on Equity

18.28%

Return on Capital

17.95%

Return on Assets

8.70%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

87.58%

Stock Overview

Market Cap

$1.13B

Shares Outstanding

50.33M

Volume

1.41M

Avg. Volume

703.21K

Financials (TTM)

Gross Profit

$4.29B

Operating Income

$2.83B

EBITDA

$3.58B

Operating Cash Flow

$3.31B

Capital Expenditure

-$1.14B

Free Cash Flow

$2.17B

Cash & ST Invst.

$5.00M

Total Debt

$4.66B

City Therapeutics Performance Analysis

City Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2024	2024-12-31	USD 2,778,000	N/A
2025	2025-12-31	USD 13,562,000	388.2%

City Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2019-09-30	-0.6%
Q4	2019-12-31	-1.3%
Q1	2020-03-31	-4.7%
Q2	2020-06-30	-72.7%

City Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2024	2024-12-31	USD -0.55	N/A
2025	2025-12-31	USD -1.16	110.2%

City Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2019-09-30	N/A
Q4	2019-12-31	N/A
Q1	2020-03-31	N/A
Q2	2020-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2020YOY CHG

Revenue

$524.00M

-74.5%

Gross Profit

$34.00M

-97.7%

Gross Margin

6.49%

N/A

Market Cap

$1.13B

N/A

Market Cap/Employee

$15.03M

N/A

Employees

N/A

Net Income

$430.00M

-9.9%

EBITDA

$910.00M

-15.5%

Quarterly Fundamentals

Name

Q2 2020YOY CHG

Total Cash

$5.00M

-28.6%

Total Debt

$4.66B

-21.7%

Accounts Receivable

$413.00M

-21.5%

Inventory

$0.00

N/A

Long Term Debt

$4.36B

-26.7%

Short Term Debt

$302.00M

+3255.6%

Return on Assets

8.70%

N/A

Return on Invested Capital

16.40%

N/A

Free Cash Flow

$410.00M

-24.6%

Operating Cash Flow

$699.00M

-9.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,659.44-0.01%

^DJIDJI

^DJIDJI$52,002.41-0.00%

^IXICNASDAQ

^IXICNASDAQ$26,140.03-0.02%

BTCBitcoin

BTCBitcoin$81,471.00+0.00%

SPCXSPCX

SPCXSPCX$146.03-0.02%

AAPLAAPL

AAPLAAPL$343.46+0.00%

AMZNAMZN

AMZNAMZN$250.00-0.02%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$89.85-5.79%

NVDANvidia

NVDANvidia$214.13-1.43%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$93.67-12.74%

CCCCCC Intelligent Solutions

CCCCCC Intelligent Solutions$7.61-0.26%

CRWVCoreWeave

CRWVCoreWeave$61.39-11.91%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.91-4.40%

RWMProShares Trust - ProShares Short Russell2000

RWMProShares Trust - ProShares Short Russell2000$14.82+1.72%

Questions About CTY

What is the current price of City Therapeutics?

City Therapeutics is trading at $22.40 per share.

What is the 52-week range for City Therapeutics?

Over the past 52 weeks, City Therapeutics has traded between $18.00 and $23.88.

How much debt does City Therapeutics have?

As of the most recent reporting period, City Therapeutics reported total debt of $211.80M.

How much cash does City Therapeutics have on hand?

City Therapeutics reported $112.79M in cash and cash equivalents in its most recent financial results.

What is City Therapeutics’s dividend yield?

City Therapeutics does not currently have a dividend yield.

City Therapeutics(NASDAQ) CTY

City Therapeutics Financials at a Glance

CTY News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About City Therapeutics

CTY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

City Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CTY

What is the current price of City Therapeutics?

What is the 52-week range for City Therapeutics?

How much debt does City Therapeutics have?

How much cash does City Therapeutics have on hand?

What is City Therapeutics’s dividend yield?

Premium Investing Services